TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Cannabidiol in Learning and Memory of Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Were 18 years of age or older~Exclusion Criteria:~* Were pregnant or breast-feeding~* Had been diagnosed with mental illness~* Didn't speak English fluently~* Had severe hearing problems~* Had recreational or opioid drug contaminants in their urine~* Were involved in criminal activity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (visit 1 drug administration) (Type: PLACEBO_COMPARATOR): 246mg Placebo, oral, single-dose (visit 1 drug administration)
- Cannabidiol (visit 1 drug administration) (Type: ACTIVE_COMPARATOR): 246mg Cannabidiol, oral single-dose (visit 1 drug administration)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of OFA in Laparoscopic Gastrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 19 years who underwent laparoscopic gastrectomy for gastric cancer~Exclusion Criteria:~* Patients with a history of allergic reactions to drugs~* Patients with a history of drug addiction~* Patients with chronic pain who require analgesics~* Patients with cancer other than the stomach~* History of hospitalization for psychiatric disorders~* Patients with sleep apnea~* Preoperative pulse oximetry (SpO2) \< 95 %~* Moderate or severe hepatic impairment~* bradycardia (HR\<50bpm), hypotension, atrioventricular block, intraventricular or sinus block~* Body mass index over 35 kg/m2~* Blood clotting disorders~* Pregnant/lactating women~* Cognitive impairment~* Unable to read consent form (eg illiterate, foreigner, etc.)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OFA group (Type: EXPERIMENTAL): Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
- Control group (Type: ACTIVE_COMPARATOR): Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
1. Inclusion and Exclusion Criteria for Individuals with Schizophrenia:~   Inclusion criteria:~  * Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) Axis 1 Diagnosis of schizophrenia~  * Wechsler Abbreviated Scale of Intelligence (WASI) intelligence quotient (IQ) \> 90~  * Currently taking antipsychotic medication~  * No change in current psychotropic medications or housing within the past 30 days. Those patients whose medication or housing situation has changed within a month, we will wait list them until their situation stabilizes.~   Exclusion criteria:~  * DSM 5 Axis 1 diagnosis other than schizophrenia~  * Diagnosed organic brain disease, brain lesions, history of head traumas, neurological disorders or other conditions that involve the degeneration of the central nervous system (e.g. multiple sclerosis)~  * Substance/alcohol dependence during the past 1 year~  * Tardive dyskinesia~2. Inclusion and Exclusion Criteria for Healthy Control Participants:~Inclusion Criteria:~* WAIS IQ \> 90.~* No DSM-5 Axis 1 diagnosis of psychotic disorders in themselves or their families (e.g. schizophrenia, bipolar disorder).~* No antipsychotic medications~* No diagnosed organic brain disease, brain lesions, history of head traumas, neurological disorders or other conditions that involve the degeneration of the central nervous system (e.g. multiple sclerosis)~* No substance/alcohol dependence during the past 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- VR Social Skills Training (Type: ACTIVE_COMPARATOR): Participants will undergo a virtual reality social skills training program for 10 sessions. Each session takes about an hour. Participants visit the lab twice a week. Therefore, the training duration is 5 weeks.
- Cognitive training game (Type: OTHER): If there is a significant improvement in social skills for the active treatment condition, the reason might be that the participants were exposed to social environment by coming to the lab and interacting with the research staff twice a week for 5 weeks and/or they used a computerized training tool twice a week for 5 weeks. In order to control for these potential confounds, we included a cognitive training arm. Participants will undergo a commercially available cognitive training program for ten 1-hour sessions (twice a week for 5 weeks).
- Healthy Controls (Type: NO_INTERVENTION): Healthy controls are recruited to yield comparison data. They do not undergo training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-70 years~* type 2 diabetes mellitus~* with or without hypertension~Exclusion Criteria:~* ischemic changes on resting electrocardiogram,~* clinical evidence of heart disease (angina, heart failure, unstable angina),cerebrovascular or peripheral vascular disease,~* significant cardiac arrhythmias,~* aortic stenosis,~* 2nd or 3rd degree atrio-ventricular block, sinus node disease, or symptomatic bradycardia,~* bronchospastic lung disease with active wheezing,~* known hypersensitivity to adenosine,~* hemoglobin A1C (HbA1c) \> 8.5%, \*~* gout (If not already taking HCTZ),~* the use of Rosiglitazone,\*\*~* estimated glomerular filtration rate (eGFR) \< 60 ml/min,~* serum potassium \> 5.0 mmol/L,~* use of potassium-sparing diuretics,\*\*~* current smoker,\*~* pregnancy,~* renal disease not related to diabetes mellitus,~* uncontrolled hypertension, systolic blood pressure (BP) \>160 mm Hg and diastolic BP \>100 mm Hg,\*~* use of cyclic hormone replacement therapy~* past intolerance of angiotensin-converting enzyme (ACE) inhibitor therapy~* other major medical illnesses. Participants with evidence of a previous myocardial infarction on the first adenosine-stimulated positron emission tomography (PET) study will be withdrawn from the study.~* Screening systolic blood pressure \< 105 mm Hg off of anti-hypertensive medications~  * Participants can enroll in study and proceed with in-patient evaluations if during the run-in period adjustments of medications, diet and habits lead to improved glucose control \[equivalent to HbA1c \<8.5%, controlled hypertension and cessation of smoking.~    * Participants who are currently taking these medications will not qualify for a screening visit. If medications were recently stopped by the participant's physician, he or she may be screened but the baseline assessment protocol must occur 3 months after stopping.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (mineralocorticoid receptor [MR] blockade) (Type: EXPERIMENTAL): None
- Hydrochlorothiazide + potassium (Type: ACTIVE_COMPARATOR): None
- Placebo capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging Study of Acute Pancreatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* acute onset of abdominal pain;~* pancreatitis at first onset;~* three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and~* abdominal MR examination.~Exclusion Criteria:~* inability to cooperate when MR imaging was performed;~* a history of chronic pancreatitis;~* AP due to pancreatic carcinoma;~* hypoproteinemia;~* with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;~* with iron deposition disorder (e.g. diabetes or blood system diseases).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- acute pancreatitis (Type: None): acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
- controlgroup (Type: None): normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nurse Initiated Acupressure for Pain Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18-80 admitted for knee or hip arthroplasty~* Pre-surgery morphine equivalent \< 50~* American Society of Anaesthesiologists (ASA) score \< 3~Exclusion Criteria:~* Participants with a history of skin disease (psoriasis), adhesive allergy, history of delirium, or cognitive impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Auricular acupressure Group (Type: EXPERIMENTAL): The Auricular acupressure (AA) nurses will place the acupressure pellet pads on the participants in this group post-operatively.
- Standard of care Group (Type: ACTIVE_COMPARATOR): Participants in this group will receive standard of care pain management by the treating physician.
- Nurse Interventionists (Type: NO_INTERVENTION): Nurses who were trained to apply the auricular acupressure pads/pellets in the the holding room prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old~* Patients having PCI with stenting 24-48 hours prior randomization, for 1. Stable angina 2.Ischaemia in provocative test 3.Acute coronary syndrome (unstable angina or myocardial infarction)~* Written Informed consent~* Platelet reactivity units (PRU) (VerifyNow) \>230~Exclusion Criteria:~* A history of bleeding diathesis~* Chronic oral anticoagulation treatment~* Contraindications to antiplatelet therapy~* Known platelet function disorders~* PCI or coronary artery bypass surgery \< 3 months~* Unsuccessful PCI (residual stenosis \> 30% or flow \< Thrombolysis in myocardial infarction flow 3)~* Planned staged PCI in the next 60 days~* Hemodynamic instability~* Cancer or hemodialysis~* Platelet count \<100 000/ μL, hematocrit \<30%~* Creatinine clearance \<25 ml/min~* A life expectancy\<1 year, inability to give informed consent~* High likelihood of being unavailable for the Day 60 follow up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- prasugrel (Type: EXPERIMENTAL): prasugrel per os 10mg/day
- clopidogrel (Type: ACTIVE_COMPARATOR): clopidogrel per os 150mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Perennial allergic rhinoconjunctivitis due to clinically relevant allergy towards house dust mite allergens~* Further criteria as defined in the study protocol~Exclusion Criteria:~* Clinically manifested seasonal allergy/-ies which is/are expected to interfere with the patient's study treatment schedule and/or assessments~* Clinically relevant perennial allergy/-ies other than house dust mites allergy~* Contraindication to any study test or procedure~* Further criteria as defined in the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Actinic keratoses in sufficient numbers (\>10) to warrant PDT therapy in the clinic~* Able to understand and willing to sign a written informed consent document~* Female subjects must not become pregnant during the study:~  * The effects of 5-aminolevulinic acid (LevulanTM) on the human fetus are unknown. For this reason, women of child-bearing potential must agree to use contraception (double barrier method of birth control or abstinence) prior to study entry, and throughout study participation. Should a woman become pregnant or suspect that she is pregnant while she is participating in this study, she should inform the treating physician immediately.~Exclusion Criteria:~* Pregnant or nursing.~* At risk for hypercalcemia (renal disease, sarcoidosis, etc.)~* Using topical retinoids, since these can exacerbate the post-PDT erythema reaction.~* Using any topical treatment on their AKs; must stop at least one month prior.~* Currently undergoing treatment for other cancers with medical or radiation therapy.~* Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.~* Patients with history of a photosensitivity disease, such as porphyria cutanea tarda.~* Currently participating in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 + Photodynamic therapy (PDT) (Type: EXPERIMENTAL): Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For Japan only: minimum age is 20 years~* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months~* Current treatment with monotherapy or combination of an insulin secretagouge (sulfonylurea or glinide) and metformin, with or without addition of alfa-glucosidase-inhibitors or a DPP-4 inhibitor with unchanged dosing for at least 3 months prior to visit 1. The dose(s) should as minimum be as stated: -Insulin secretagogue (sulfonylurea or glinide): Minimum half of the daily maximal dose according to local labelling -Metformin: alone or in combination (including fixed combination): Maximum tolerated dose - alfa-glucosidase-inhibitors: Minimum half of the daily maximal dose or maximum tolerated dose -DPP-4 (dipeptyl peptidase 4) inhibitor: According to local labelling~* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis~* Body Mass Index (BMI) no higher than 35.0 kg/m\^2~Exclusion Criteria:~* Use within the last 3 months prior to Visit 1 of: TZDs (thiazolidinediones), exenatide or liraglutide~* Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)~* Pregnancy, breast-feeding, or the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements (for Thailand: adequate contraceptive measures are: diaphragm, condom (by the partner), intrauterine device in place for last three months before trial starts, sponge, cap with spermicide, contraceptive patch, approved hormonal implant (i.e. Norplant), oral contraceptives taken without difficulty for the last three months before trial starts, post menopausal state or sterilisation.)~* Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary squamous, basaloid, or cloacogenic carcinoma of the anal canal, other than carcinoma in situ~  * T2-4, Any N, M0 (stage II or III)~* No local or regional recurrence after local excision or abdominal peritoneal resection~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 4,000/mm\^3~* Absolute neutrophil count at least 1,800/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic:~* Bilirubin less than 1.4 mg/dL~Renal:~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance at least 80 mL/min~Cardiovascular:~* No uncompensated heart disease~* No uncontrolled high blood pressure~Other:~* No AIDS~* No active systemic infection~* No uncontrolled diabetes~* No other prior malignancy within the past 5 years except nonmelanoma skin cancer~* No mental condition that would preclude study participation~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Prior epoetin alfa allowed in lieu of blood transfusions~Chemotherapy:~* At least 5 years since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 5 years since prior radiotherapy~Surgery:~* No prior surgery of anal canal except for biopsy of study site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete